hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
hVIVO strengthens Board with appointment of Richard Cotton as Non-Executive Director Seasoned life sciences executive with extensive Board and financial expertise
Shore Capital has maintained its Buy rating on hVIVO PLC, the specialist contract research organisation, with a fair value assessment of 25 pence per share.
Small-cap stocks represent some of the more appealing opportunities for investors who enjoy diversifying their portfolios and capitalizing on high growth potential. The typical small-cap company, within the valuation bracket
Brighton, United Kingdom – 12 August 2024 – Destiny Pharma plc (AIM: DEST), a clinical-stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life-threatening
Cambridge, UK, 15 February 2024 – Sareum Holdings plc (AIM: SAR), a clinical-stage biotechnology company developing next generation kinase inhibitors for autoimmune disease and cancer, today announces the completion of the single ascending
Tiziana Life Science Ltd is a biopharmaceutical firm in the clinical stage that develops breakthrough therapies by utilizing transformational drug-delivery technologies.
Redx Pharma PLC (AIM: REDX) announced that its primary asset, RXC007, is successfully moving through phase IIa testing, with anticipated results from the idiopathic pulmonary fibrosis research due in the
Cellular Goods (LSE: CBX), a UK-based skincare and wellness company providing premium consumer products formulated with lab-produced cannabinoids, is pleased to announce that it has entered into a contract with
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO), a biopharmaceutical company focused on ophthalmology, is set to present two papers on their treatment for dry eye disease (DED), OK-101, at the
Activation of First Clinical Trial Site in the U.S
OKYO Pharma Ltd (LSE: OKYO, NASDAQ: OKYO) announced that the ClinicalTrials.gov public website (ClinicalTrials.gov Identifier: NCT05759208) now includes information about its trial that assesses the safety and effectiveness of OK-101
OKYO Pharma Announces Custom Clearance of GMP Packaged OK-101 Drug to be Used in Phase 2 Clinical Trial for Treating Dry Eye Disease